Clinical trial · no report yet · Phase 2
NUTRIVENTION-4
A Study of Health-Related Quality of Life in People With Multiple Myeloma Receiving Daratumumab or Lenalidomide
- NCT04497961 ↗
- Active, not recruiting
- Memorial Sloan Kettering Cancer Center
- Focused
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| X threads | 2 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- Daratumumab Versus Lenalidomide Maintenance Therapy for Multiple Myeloma: A Randomized Pilot Study Comparing Patient-Reported Health Related Quality of Life Measures With a Plant Based Nutrition Intervention Sub Study (NUTRIVENTION-4)
- Phase
- Phase 2
- Status
- Active, not recruiting
- Conditions
- Multiple Myeloma
- Interventions
- Lenalidomide; Daratumumab; Questionnaires; Dietary Intervention
- Arms
- Lenalidomide maintenance · Experimental
- Daratumumab maintenance · Experimental
- Enrollment
- 95
- Primary outcomes
- Difference in the global health status
- Sponsor
- Memorial Sloan Kettering Cancer Center with Janssen Scientific Affairs, LLC
- Start
- Aug 28, 2020
- Primary completion
- Aug 2027 (estimated)
- Results posted
- No
- Registry record
- NCT04497961 · updated Sep 15, 2026